Eleven patients were operated on for metachronous primary lung carcinomas. Most patients were heavy smokers. The incidence of primary metachronous carcinomas suitable for the operation was 0.45% of primary lung malignancies operated on during the same period. The mean interval between the first and second operations was 47.3 months. Surgical mortality was 0 after the first operation and 18% (2 out of 11 patients) after the second operation. The second primary malignant tumours were more advanced than the first ones. Two patients were alive at the follow-up 9 and 52 months after the second operation. The cause of the death was pulmonary carcinoma in five patients and respiratory and renal failure in one patient and respiratory insufficiency in one patient. Our findings suggest that reoperation for second primary lung malignant tumours should only be performed if the diagnosis is established early enough and if the primary operation was considered to be radical.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases.
Sci Rep
January 2025
Department of Radiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, Hubei, China.
Brain metastases (BM) are the most prevalent intracranial malignancies. Approximately 30-40% of cancer patients develop BM at some stage of their illness, presenting with a high incidence and poor prognosis. Our clinical findings indicate a significant disparity in the efficacy between non-enhanced and enhanced lung cancer BM.
View Article and Find Full Text PDFCombination of Carbonic Anhydrase Isoform IX Inhibitors and Gefitinib Suppresses on the Invasive Potential of Non-Small Cell Lung Cancer Cells.
Biochemistry (Mosc)
December 2024
Medicinal Chemistry Center, Togliatti State University, Togliatti, 445020, Russia.
Human carbonic anhydrase IX (CAIX) plays a key role in maintaining pH homeostasis of malignant neoplasms, thus creating a favorable microenvironment for the growth, invasion, and metastasis of tumor cells. Recent studies have established that inhibition of CAIX expressed on the surface of tumor cells significantly increases the efficacy of classical chemotherapeutic agents and makes it possible to suppress the resistance of tumor cells to chemotherapy, as well as to increase their sensitivity to drugs (in particular, to reduce the required dose of cytostatic agents). In this work, we studied the ability of new CAIX inhibitors based on substituted 1,2,4-oxadiazole-containing primary aromatic sulfonamides, to potentiate the cytostatic effect of gefitinib (selective inhibitor of epidermal growth factor receptor tyrosine kinase domain) under hypoxic conditions.
View Article and Find Full Text PDFPerformance of an Electronic Health Record-Based Automated Pulmonary Embolism Severity Index Score Calculator: Cohort Study in the Emergency Department.
JMIR Med Inform
January 2025
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, United States.
Background: Studies suggest that less than 4% of patients with pulmonary embolisms (PEs) are managed in the outpatient setting. Strong evidence and multiple guidelines support the use of the Pulmonary Embolism Severity Index (PESI) for the identification of acute PE patients appropriate for outpatient management. However, calculating the PESI score can be inconvenient in a busy emergency department (ED).
View Article and Find Full Text PDFEarly Renal Failure After Primary Thoracic Organ Transplantation.
J Heart Lung Transplant
January 2025
The International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, Chicago, IL.
Poor agreement among asthma specialists on the choice and timing of initiation of a biologic treatment for severe asthma patients.
J Allergy Clin Immunol Pract
January 2025
Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care Global, Cambridge, UK; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. Electronic address:
Background: As the number of monoclonal antibodies available for severe asthma is growing, specialists currently choose without clear guidelines. Despite increasing knowledge on treatment response to these monoclonal antibodies, making the optimal choice for each individual patient remains a challenge. However, evidence of this daily challenge is lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!